Robert Joined Westwicke Partners in 2011 as a member of the life science team, and works with public and private specialty pharmaceutical and biotechnology companies.
Robert has over 20 years’ Wall Street experience on both the sell-side and buy-side, primarily as a financial analyst and director of equity research. Prior to joining Westwicke, Robert served as Senior Director, Investor Relations with Halozyme Therapeutics, with responsibility for all investment community communications, including details of Halozyme’s business plan and development programs in oncology, immunology and diabetes.
Robert has spent most of his career as a healthcare financial analyst following the branded and generic pharmaceutical and biotechnology sectors and, as director of equity research, including roles as a vice president and specialty pharmaceuticals analyst with FBR Capital Markets in Arlington, Virginia Leerink, Swann & Co., Salomon Brothers, and Curran Capital Management.
Robert earned a BS in microbiology from Purdue University and an MBA in international business studies from the University of South Carolina.